Aeterna Zentaris Reports First Quarter 2024 Financial Results
14 mai 2024 18h00 HE
|
Aeterna Zentaris Inc
Company ended the quarter with $29.5 million in cashDETECT-trial recruitment completed; Company continues to expect the completion of the trial in the second quarter and top-line data in the third...
Aeterna Zentaris to Participate in the Virtual Investor Summer Spotlight Series
05 juil. 2023 08h45 HE
|
Aeterna Zentaris Inc
Live moderated video webcast on Thursday, July 13th at 10:00 AM ET TORONTO, ONTARIO, July 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the...
Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson’s Disease
12 mai 2022 08h05 HE
|
Aeterna Zentaris Inc
– Data presented at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists – Company advancing development of its Autoimmunity Modifying (“AIM”) Biologicals as a potential...
Aeterna Zentaris to Participate at the Virtual Investor 2022 CEO Spotlight
12 avr. 2022 08h05 HE
|
Aeterna Zentaris Inc
– Live moderated video webcast fireside chat with Dr. Klaus Paulini, CEO and Giuliano La Fratta, CFO of Aeterna Zentaris, on Thursday, April 14th at 10:00 AM ET TORONTO, ONTARIO, April 12, 2022 ...
Aeterna Zentaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Outlook
29 mars 2022 08h00 HE
|
Aeterna Zentaris Inc
– Continue to advance and expand opportunities with established diversified development pipeline – Company ended the year with $65.3 million in cash, expected to fund operations through 2023 ...
Aeterna Zentaris Provides Business Outlook and Outlines Pipeline Priorities
26 janv. 2022 08h05 HE
|
Aeterna Zentaris Inc
– Company advancing diversified portfolio focused on areas of significant unmet medical need– Supported by solid financial position with cash to fund operations beyond 2023 TORONTO,...
Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s Disease)
17 mai 2021 08h05 HE
|
Aeterna Zentaris Inc
- Aeterna Zentaris granted exclusive option to negotiate a license of any resulting intellectual property and know-how developed by the University related to the therapeutic use of macimorelin for the...
Aeterna Zentaris Announces the Selection of a Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism
06 mai 2021 08h05 HE
|
Aeterna Zentaris Inc
–In collaboration, Aeterna and The University of Sheffield, UK have selected the development candidate AEZS-150, a parathyroid hormone (PTH) fusion polypeptide to start the formal preclinical...
Aeterna Zentaris Reports First Quarter 2021 Financial Results and Provides Pipeline Program Updates
05 mai 2021 08h05 HE
|
Aeterna Zentaris Inc
– Q1 2021 marked by solid operational execution with expansion and diversification of pipeline, intellectual property and portfolio of assets – Pivotal Phase 3 DETECT (Study P02)...
Aeterna Zentaris to Present at the H.C. Wainwright Global Life Sciences Conference
24 févr. 2021 08h05 HE
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing...